Earnings Releases·Nov 5, 2026, 4:07 PM ET

CytomX Therapeutics — Q3 2026 Earnings Summary

Revenue declined to $1.7 million from $6.0 million year-over-year due to the conclusion of the Astellas collaboration performance obligation, while operating expenses rose to $25.2 million from $21.7 million, driven by personnel, consulting, and rent costs associated with the new Emeryville headquarters.
Net loss widened to $20.0 million from $14.2 million in the prior year period, though cash and investments increased to $348.0 million, extending the cash runway into the second half of 2028.
Varseta-M received FDA Fast Track designation for relapsed/refractory mCRC in August 2026, with management targeting a Phase 1 monotherapy data update in January 2027 and the initiation of a potential first registrational study in the first half of 2027.
Additional clinical milestones include plans to initiate a Phase 1/2 combination study with bevacizumab, 5-fluorouracil, and leucovorin by the end of 2026, alongside anticipated initial data for Varseta-M/bevacizumab and CX-801/KEYTRUDA® combinations in the first half of 2027.